To what extent do patients in general practice reach guideline lipid-lowering treatment goals?

European Journal of Preventive Cardiology

Volumn 14, Issue 1, 2007, Pages 149-151

  Kristiansson, Per ^a   Björholt, Ingela ^b   Siewert Delle, Annica ^c   Svärdsudd, Kurt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

lipid lowering treatment; statin treatment; treatment goals

Indexed keywords

CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; STATIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG DOSE TITRATION; FEMALE; GENERAL PRACTICE; GOAL ATTAINMENT; HEALTH CENTER; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SWEDEN;

AGED; ANTICHOLESTEREMIC AGENTS; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; SWEDEN;

EID: 33847064617     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3280125485     Document Type: Article

References (18)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
2. Shepard J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
3. Heart Protection Study Collaboration Group. MRC∖BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
4. Beerman B. New recommendations on the treatment of hyperlipidaemia [in Swedish], vol 3. Uppsala: Medical Products Agency; 1995. pp. 178–203.
5. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199–270.
6. Task force report. Medical Product Agency's recommendations. Uppsala: Medical Products Agency; 2003.
7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
8. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995–1001.
9. Bowker TJ, Clayton TC, Ingham J, McLennan NR, Hobson HL, Pyke SD, et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334–342.
10. Kahan T, Wandell P. Risk factors in established coronary heart disease: evaluation of a secondary prevention programme. J Cardiovasc Risk 2001; 8: 1–8.
11. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711–717.
12. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002; 176: 211–215.
13. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.
14. Wandell PE, Gåfvels C. Metabolic control and quality of data in medical records for subjects with type 2 diabetes in Swedish primary care: improvement between 1995 and 2001. Scand J Prim Health Care 2002; 20: 230–235.
15. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 1322–1325.
16. Wright DJ, Grayson AD, Jackson M, Dainty C. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey. Int J Clin Pract 2003; 57: 459–460.
17. Svilaas A, Risberg K, Thoresen M, Ose L. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 2000; 86: 1250–1253.
18. Hippisley-Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003; 326: 689–693.